InSilico Medicine Cayman TopCo (abbreviated as INSILICO) will convene its 2026 annual general meeting (AGM) electronically on 2 June 2026 at 9:00 a.m. via the company’s eVoting Portal.

Key agenda items:

1. Financial reporting • Shareholders will review and adopt the audited consolidated financial statements and the directors’ and auditor’s reports for the year ended 31 December 2025.

2. Board composition and remuneration • Re-election of five directors: executive directors Dr. Aleksandrs Zavoronkovs and Dr. Feng Ren; independent non-executive directors Dr. Denitsa Milanova, Dr. Jingsong Wang and Mr. Roman Kyrychynskyi. • The board will be authorized to determine directors’ remuneration.

3. Auditor re-appointment • Deloitte Touche Tohmatsu is nominated for re-appointment as external auditor, with the board empowered to set audit fees.

4. Capital management mandates • Share repurchase mandate: directors may repurchase up to 10% of issued shares (excluding treasury shares) on the Hong Kong Stock Exchange or other recognized bourses during the mandate period. • Share issuance mandate: directors may allot, issue or deal with new shares—excluding specific share schemes and corporate actions—up to 20% of issued share capital (excluding treasury shares). • Extension mandate: the issuance limit may be increased by the number of shares repurchased under the above buy-back authorization, capped at an additional 10% of issued shares.

Administrative details: • The share register will be closed from 28 May to 2 June 2026 (both days inclusive). Shareholders must ensure transfers are lodged with Tricor Investor Services by 4:30 p.m. on 27 May 2026 to qualify for voting. • Proxy forms must reach Tricor Investor Services by 9:00 a.m. on 31 May 2026. Voting at the AGM will be conducted by poll.

The notice is dated 28 April 2026 and signed by Chairman, Executive Director, CEO and CBO Dr. Aleksandrs Zavoronkovs on behalf of the board.